ALPS Advisors’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

ALPS Advisors’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-78,042	Closed	-$521K	–	1022
2023 Q3	$521K	Sell	78,042 -2,144	-3%	-$17.8K	﹤0.01%	593
2023 Q2	$726K	Buy	80,186 +10,583	+15%	+$93.3K	0.01%	548
2023 Q1	$506K	Sell	69,603 -2,009	-3%	-$14.9K	﹤0.01%	591
2022 Q4	$522K	Buy	71,612 +22,434	+46%	+$166K	﹤0.01%	582
2022 Q3	$380K	Sell	49,178 -6,302	-11%	-$53.5K	﹤0.01%	667
2022 Q2	$378K	Buy	+55,480	New	+$425K	﹤0.01%	665

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

ALPS Advisors's PNT Position: Q4 2023 in Review

ALPS Advisors sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 78,042 shares — an estimated $521K sold.

ALPS Advisors first reported a position in PNT in Q2 2022 and held it in 6 quarters. The position peaked at $726K in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

ALPS Advisors reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
ALPS Advisors sold 78,042 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $521K.
ALPS Advisors first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2022 and held it in 6 quarters.
ALPS Advisors's POINT Biopharma Global Inc. Common Stock position peaked at $726K in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on ALPS Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.